In CLL, for instance, nearly every patient demonstrates Bcl-2 overexpression; a consequence of genomic deletion (13q14) impairing the microRNA inhibitors of Bcl-2 (miR15 and miR16) in half of these patients. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.